Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The valuation profile exhibits a period of significant volatility in earnings multiples during 2023 and 2024, followed by a broad expansion across all valuation metrics starting in late 2025. This progression suggests a shift in market valuation or an increase in the premium attributed to the equity toward the end of the observed timeframe.
- Price to Earnings (P/E)
- The P/E ratio experienced extreme fluctuations. After remaining stable near 24 in early 2022, it spiked to 33.43 in April 2023 before undergoing a sharp contraction to a period low of 9.46 by March 2024. A sustained recovery followed, with the ratio climbing steadily from 17.14 in December 2024 to a peak of 29.70 by June 2026.
- Price to Operating Profit (P/OP)
- The P/OP ratio demonstrated greater stability than the P/E ratio, primarily oscillating between 15.69 and 19.83 from 2022 through mid-2025. An upward trend became evident in the final quarters, with the ratio increasing to 24.10 by June 2026, reflecting a rise in the valuation multiple relative to operating performance.
- Price to Sales (P/S)
- The P/S ratio remained relatively constant between 4.01 and 5.00 for the majority of the period. However, a notable expansion occurred starting in late 2025, where the ratio broke its historical range to reach 6.16 in December 2025 and eventually 6.38 by June 2026.
- Price to Book Value (P/BV)
- A pattern similar to the P/S ratio is observed in the P/BV metric. The ratio fluctuated between 4.79 and 6.36 from April 2022 through mid-2025. A significant upward trajectory began in the latter part of 2025, culminating in a peak of 7.35 by June 2026, indicating an increase in the market value relative to the company's book value.
AI Ask an analyst for more
Price to Earnings (P/E)
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,409,898,597 | 2,407,216,971 | 2,409,898,936 | 2,409,295,102 | 2,408,338,872 | 2,406,073,279 | 2,407,616,693 | 2,407,622,972 | 2,407,243,667 | 2,406,679,183 | 2,408,767,228 | 2,407,278,620 | 2,598,969,594 | 2,598,734,075 | 2,604,286,303 | 2,614,483,607 | 2,629,179,895 | 2,631,401,804 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||
| Net earnings (loss) (in millions) | 5,534) | 5,235) | 5,116) | 5,152) | 5,537) | 10,999) | 3,431) | 2,694) | 4,686) | 3,255) | 4,049) | 26,028) | 5,144) | (68) | 3,520) | 4,458) | 4,814) | 5,149) | ||||||
| Earnings per share (EPS)2 | 8.73 | 8.74 | 11.12 | 10.43 | 9.41 | 9.06 | 5.84 | 6.10 | 15.79 | 15.99 | 14.59 | 14.38 | 5.02 | 4.90 | 6.89 | 7.33 | 6.99 | 7.54 | ||||||
| Share price1, 3 | 259.27 | 226.10 | 240.86 | 192.94 | 169.56 | 155.38 | 157.25 | 165.86 | 159.64 | 151.18 | 156.55 | 145.60 | 167.53 | 163.70 | 158.24 | 172.31 | 174.52 | 180.46 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||
| P/E ratio4 | 29.70 | 25.87 | 21.66 | 18.51 | 18.02 | 17.14 | 26.92 | 27.19 | 10.11 | 9.46 | 10.73 | 10.12 | 33.35 | 33.43 | 22.97 | 23.52 | 24.98 | 23.95 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||
| AbbVie Inc. | — | 97.96 | 94.06 | 159.78 | 92.57 | 77.73 | 79.59 | 69.16 | 62.04 | 48.26 | 63.84 | 38.27 | 30.55 | 34.43 | 22.62 | 19.16 | 19.44 | 21.64 | ||||||
| Amgen Inc. | — | 22.82 | 25.81 | 24.59 | 23.15 | 25.49 | 38.24 | 40.68 | 53.65 | 44.38 | 23.14 | 18.09 | 16.31 | 16.18 | 19.56 | 21.00 | 20.03 | 22.23 | ||||||
| Bristol-Myers Squibb Co. | 14.27 | 17.01 | 17.30 | 15.38 | 17.46 | 18.29 | — | — | — | — | 12.27 | 13.01 | 15.93 | 19.43 | 23.97 | 23.71 | 24.14 | 25.64 | ||||||
| Danaher Corp. | 31.43 | 37.32 | 40.93 | 44.52 | 39.84 | 36.51 | 38.12 | 48.49 | 45.39 | 42.59 | 39.09 | 24.76 | 29.99 | 25.00 | 25.65 | 26.65 | 32.73 | 32.15 | ||||||
| Eli Lilly & Co. | — | 34.82 | 47.45 | 43.36 | 43.95 | 67.76 | 77.63 | 96.05 | 109.42 | 120.94 | 135.24 | 110.43 | 76.21 | 65.16 | 50.08 | 55.53 | 51.05 | 45.29 | ||||||
| Gilead Sciences Inc. | — | 18.06 | 21.54 | 18.18 | 21.68 | 20.62 | 296.57 | 925.87 | 89.29 | 166.76 | 16.17 | 17.10 | 17.88 | 17.75 | 22.68 | 29.30 | 18.66 | 17.25 | ||||||
| Merck & Co. Inc. | — | 31.27 | 16.79 | 11.00 | 12.30 | 11.98 | 13.49 | 20.98 | 20.73 | 140.05 | 893.99 | 56.85 | 86.53 | 22.92 | 19.21 | 16.41 | 13.36 | 15.70 | ||||||
| Pfizer Inc. | — | 20.12 | 19.83 | 14.06 | 13.09 | 17.22 | 18.42 | 37.00 | — | — | 73.42 | 16.60 | 9.42 | 7.44 | 7.58 | 8.81 | 9.56 | 11.11 | ||||||
| Regeneron Pharmaceuticals Inc. | 17.56 | 16.27 | 18.19 | 15.03 | 13.29 | 13.65 | 17.76 | 19.79 | 27.88 | 26.78 | 25.99 | 22.35 | 19.48 | 19.77 | 19.68 | 14.98 | 11.67 | 9.15 | ||||||
| Thermo Fisher Scientific Inc. | 30.48 | 25.46 | 28.82 | 32.45 | 26.56 | 24.55 | 32.03 | 34.78 | 37.81 | 36.21 | 35.65 | 29.57 | 37.01 | 34.99 | 30.55 | 27.64 | 31.09 | 28.15 | ||||||
| Vertex Pharmaceuticals Inc. | — | 24.83 | 31.58 | 29.11 | 26.43 | — | — | — | — | 26.34 | 30.42 | 28.09 | 27.49 | 27.34 | 23.02 | 24.62 | 23.12 | 26.50 | ||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
EPS
= (Net earnings (loss)Q2 2026
+ Net earnings (loss)Q1 2026
+ Net earnings (loss)Q4 2025
+ Net earnings (loss)Q3 2025)
÷ No. shares of common stock outstanding
= (5,534,000,000 + 5,235,000,000 + 5,116,000,000 + 5,152,000,000)
÷ 2,409,898,597 = 8.73
3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.
4 Q2 2026 Calculation
P/E ratio = Share price ÷ EPS
= 259.27 ÷ 8.73 = 29.70
5 Click competitor name to see calculations.
An analysis of the valuation metrics reveals significant volatility in the Price-to-Earnings (P/E) ratio, driven by substantial fluctuations in both share price and earnings per share (EPS) over the observed period. The relationship between these two variables suggests periods of earnings instability followed by a sustained expansion of the valuation multiple toward the end of the series.
- Share Price Performance
- The share price exhibited a gradual decline from April 2022, reaching a cyclical low of 145.60 USD in October 2023. Following this trough, a recovery phase began, accelerating sharply between June 2025 and December 2025, where the price rose from 169.56 USD to 240.86 USD. The period concluded with a peak of 259.27 USD in June 2026, representing a significant appreciation from the 2023 lows.
- Earnings Per Share (EPS) Volatility
- EPS demonstrated erratic movements, most notably a dramatic spike between October 2023 and June 2024, where values surged from 14.38 USD to a peak of 15.99 USD. This surge was followed by a sharp correction in September 2024, with EPS dropping to 6.10 USD. A subsequent recovery trend saw earnings climb back to 11.12 USD by December 2025 before stabilizing around 8.73 USD in the first half of 2026.
- P/E Ratio Trends and Interpretation
- The P/E ratio experienced three distinct phases. Initially, the ratio remained relatively stable between 23x and 25x throughout 2022. A period of extreme volatility occurred between April 2023 and December 2024; the ratio spiked to 33.43x during an earnings dip in early 2023, collapsed to a low of 9.46x during the EPS surge of March 2024, and rebounded to 27.19x by September 2024. In the final phase, from March 2025 onward, the P/E ratio showed a consistent upward trajectory, expanding from 17.14x to 29.70x by June 2026, indicating increased investor willingness to pay a premium per dollar of earnings.
The overall trend indicates that while the mid-period valuation was heavily influenced by anomalous earnings fluctuations, the latter portion of the timeline reflects a fundamental shift in valuation, characterized by simultaneous growth in share price and an expanding P/E multiple.
AI Ask an analyst for more
Price to Operating Profit (P/OP)
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,409,898,597 | 2,407,216,971 | 2,409,898,936 | 2,409,295,102 | 2,408,338,872 | 2,406,073,279 | 2,407,616,693 | 2,407,622,972 | 2,407,243,667 | 2,406,679,183 | 2,408,767,228 | 2,407,278,620 | 2,598,969,594 | 2,598,734,075 | 2,604,286,303 | 2,614,483,607 | 2,629,179,895 | 2,631,401,804 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||
| Operating earnings (in millions) | 7,140) | 6,327) | 5,426) | 7,033) | 6,646) | 6,182) | 3,582) | 5,037) | 6,276) | 5,909) | 4,193) | 5,534) | 5,813) | 5,667) | 5,331) | 6,216) | 6,087) | 5,748) | ||||||
| Operating profit per share2 | 10.76 | 10.56 | 10.49 | 9.73 | 8.91 | 8.76 | 8.64 | 8.89 | 9.10 | 8.91 | 8.80 | 9.28 | 8.86 | 8.97 | 8.98 | 8.78 | 8.53 | 8.57 | ||||||
| Share price1, 3 | 259.27 | 226.10 | 240.86 | 192.94 | 169.56 | 155.38 | 157.25 | 165.86 | 159.64 | 151.18 | 156.55 | 145.60 | 167.53 | 163.70 | 158.24 | 172.31 | 174.52 | 180.46 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||
| P/OP ratio4 | 24.10 | 21.40 | 22.95 | 19.83 | 19.04 | 17.74 | 18.20 | 18.65 | 17.54 | 16.96 | 17.78 | 15.69 | 18.91 | 18.26 | 17.62 | 19.64 | 20.45 | 21.06 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||
| AbbVie Inc. | — | 23.23 | 26.37 | 42.20 | 31.76 | 32.37 | 37.26 | 25.63 | 26.99 | 22.62 | 24.34 | 16.55 | 15.26 | 16.15 | 14.78 | 14.52 | 14.12 | 14.57 | ||||||
| Amgen Inc. | — | 16.84 | 21.92 | 19.86 | 18.71 | 20.31 | 21.55 | 27.68 | 27.12 | 23.97 | 19.69 | 15.45 | 13.71 | 14.25 | 13.40 | 14.89 | 14.08 | 15.88 | ||||||
| Bristol-Myers Squibb Co. | 11.30 | 12.42 | 12.20 | 10.25 | 11.07 | 13.65 | — | — | — | — | 13.53 | 14.14 | 16.24 | 17.09 | 18.29 | 17.79 | 18.62 | 20.32 | ||||||
| Danaher Corp. | 24.54 | 28.93 | 31.54 | 33.80 | 30.79 | 28.49 | 30.56 | 39.52 | 38.14 | 37.52 | 35.64 | 23.61 | 27.01 | 21.31 | 20.97 | 20.71 | 25.91 | 26.48 | ||||||
| Eli Lilly & Co. | — | 27.92 | 37.24 | 34.60 | 35.19 | 53.43 | 63.73 | 79.30 | 88.66 | 99.34 | 109.75 | 93.27 | 69.42 | 59.60 | 43.88 | 46.48 | 39.20 | 36.49 | ||||||
| Gilead Sciences Inc. | — | 16.05 | 18.29 | 14.06 | 17.00 | 14.96 | 85.65 | 143.05 | 36.80 | 51.26 | 12.05 | 12.16 | 11.57 | 11.21 | 14.21 | 16.27 | 11.02 | 10.78 | ||||||
| Merck & Co. Inc. | — | 23.37 | 14.44 | 9.67 | 10.57 | 10.37 | 11.60 | 18.67 | 18.41 | 75.94 | 138.56 | 33.75 | 44.67 | 18.53 | 15.55 | 13.85 | 11.72 | 14.29 | ||||||
| Pfizer Inc. | — | 10.37 | 10.82 | 10.07 | 9.49 | 11.27 | 11.92 | 27.24 | — | — | 121.63 | 17.49 | 9.17 | 6.74 | 6.80 | 7.82 | 9.11 | 11.49 | ||||||
| Regeneron Pharmaceuticals Inc. | 19.78 | 19.83 | 22.90 | 18.65 | 15.42 | 16.03 | 19.63 | 23.18 | 30.86 | 26.82 | 25.39 | 21.13 | 19.32 | 18.68 | 18.01 | 12.91 | 9.68 | 7.98 | ||||||
| Thermo Fisher Scientific Inc. | 26.07 | 22.09 | 24.94 | 28.40 | 23.62 | 21.64 | 27.65 | 29.74 | 32.66 | 31.40 | 31.16 | 25.59 | 31.55 | 29.54 | 25.30 | 21.43 | 23.99 | 21.84 | ||||||
| Vertex Pharmaceuticals Inc. | — | 23.01 | 29.92 | 26.79 | 24.50 | — | — | — | — | 25.25 | 28.74 | 25.14 | 23.33 | 22.03 | 17.75 | 19.41 | 18.11 | 22.13 | ||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
Operating profit per share
= (Operating earningsQ2 2026
+ Operating earningsQ1 2026
+ Operating earningsQ4 2025
+ Operating earningsQ3 2025)
÷ No. shares of common stock outstanding
= (7,140,000,000 + 6,327,000,000 + 5,426,000,000 + 7,033,000,000)
÷ 2,409,898,597 = 10.76
3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.
4 Q2 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 259.27 ÷ 10.76 = 24.10
5 Click competitor name to see calculations.
The analysis of the Price to operating profit (P/OP) ratio reveals a cyclical valuation pattern characterized by an initial contraction, a period of stabilization, and a subsequent significant expansion.
- Share Price Trajectory
- A downward trend is observed from April 2022, with the share price declining from 180.46 US$ to a period low of 145.60 US$ by October 2023. Following this trough, a recovery phase began, accelerating sharply in late 2025 and continuing through June 2026, where the price reached a peak of 259.27 US$.
- Operating Profit per Share Performance
- Operating profit per share remained relatively range-bound between 8.53 US$ and 9.28 US$ from April 2022 through December 2024. A positive shift occurred starting in September 2025, with values increasing steadily to reach 10.76 US$ by June 2026, indicating an improvement in underlying operational efficiency or revenue growth during the final stage of the period.
- P/OP Ratio Dynamics
- The P/OP ratio experienced significant volatility, beginning at 21.06 in April 2022 and compressing to 15.69 by October 2023, reflecting a decrease in market valuation relative to operating earnings. Between December 2023 and June 2025, the ratio stabilized, fluctuating within a narrow band between 16.96 and 19.04. A notable valuation expansion occurred from June 2025 onward, with the ratio climbing to 24.10 by June 2026.
- Correlation Analysis
- The expansion of the P/OP ratio in the final quarters is primarily driven by share price appreciation outstripping the growth in operating profit. While operating profit per share grew by approximately 20% between June 2025 and June 2026, the share price increased by approximately 53% over the same interval, leading to the observed peak in the valuation multiple.
AI Ask an analyst for more
Price to Sales (P/S)
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,409,898,597 | 2,407,216,971 | 2,409,898,936 | 2,409,295,102 | 2,408,338,872 | 2,406,073,279 | 2,407,616,693 | 2,407,622,972 | 2,407,243,667 | 2,406,679,183 | 2,408,767,228 | 2,407,278,620 | 2,598,969,594 | 2,598,734,075 | 2,604,286,303 | 2,614,483,607 | 2,629,179,895 | 2,631,401,804 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||
| Sales to customers (in millions) | 25,310) | 24,062) | 24,564) | 23,993) | 23,743) | 21,893) | 22,520) | 22,471) | 22,447) | 21,383) | 21,395) | 21,351) | 21,519) | 20,894) | 23,706) | 23,791) | 24,020) | 23,426) | ||||||
| Sales per share2 | 40.64 | 40.03 | 39.09 | 38.25 | 37.63 | 37.13 | 36.89 | 36.42 | 35.96 | 35.59 | 35.35 | 36.34 | 34.59 | 35.56 | 36.46 | 36.73 | 36.36 | 36.06 | ||||||
| Share price1, 3 | 259.27 | 226.10 | 240.86 | 192.94 | 169.56 | 155.38 | 157.25 | 165.86 | 159.64 | 151.18 | 156.55 | 145.60 | 167.53 | 163.70 | 158.24 | 172.31 | 174.52 | 180.46 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||
| P/S ratio4 | 6.38 | 5.65 | 6.16 | 5.04 | 4.51 | 4.19 | 4.26 | 4.55 | 4.44 | 4.25 | 4.43 | 4.01 | 4.84 | 4.60 | 4.34 | 4.69 | 4.80 | 5.00 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||
| AbbVie Inc. | — | 5.67 | 6.50 | 6.40 | 5.97 | 5.68 | 6.04 | 6.38 | 6.02 | 5.32 | 5.72 | 4.52 | 4.74 | 4.60 | 4.61 | 4.44 | 4.28 | 4.76 | ||||||
| Amgen Inc. | — | 5.02 | 5.66 | 4.99 | 4.57 | 4.61 | 4.88 | 5.53 | 5.68 | 5.93 | 5.78 | 5.34 | 5.14 | 5.14 | 5.17 | 5.85 | 5.35 | 5.21 | ||||||
| Bristol-Myers Squibb Co. | 2.69 | 2.55 | 2.53 | 1.93 | 1.85 | 2.08 | 2.36 | 2.38 | 2.20 | 1.99 | 2.19 | 2.40 | 2.81 | 3.10 | 3.29 | 3.39 | 3.39 | 3.41 | ||||||
| Danaher Corp. | 5.01 | 5.56 | 6.02 | 6.43 | 5.66 | 5.77 | 6.23 | 7.95 | 8.10 | 7.90 | 7.76 | 5.63 | 6.77 | 5.76 | 5.79 | 5.66 | 6.59 | 6.68 | ||||||
| Eli Lilly & Co. | — | 12.18 | 15.03 | 13.44 | 11.39 | 15.36 | 18.25 | 19.67 | 20.64 | 20.66 | 20.77 | 17.18 | 16.78 | 13.38 | 10.96 | 11.46 | 9.99 | 9.47 | ||||||
| Gilead Sciences Inc. | — | 5.69 | 6.34 | 5.16 | 4.76 | 4.31 | 4.98 | 4.18 | 3.41 | 2.97 | 3.40 | 3.69 | 3.61 | 3.70 | 3.86 | 3.64 | 2.84 | 2.86 | ||||||
| Merck & Co. Inc. | — | 4.25 | 4.71 | 3.26 | 3.17 | 3.27 | 3.60 | 4.03 | 4.56 | 5.26 | 5.43 | 4.42 | 4.62 | 5.16 | 4.71 | 4.25 | 3.87 | 4.12 | ||||||
| Pfizer Inc. | — | 2.38 | 2.46 | 2.20 | 2.20 | 2.17 | 2.32 | 2.60 | 3.00 | 2.86 | 2.61 | 2.51 | 2.58 | 2.32 | 2.37 | 2.63 | 2.77 | 3.00 | ||||||
| Regeneron Pharmaceuticals Inc. | 4.89 | 4.82 | 5.71 | 4.83 | 4.17 | 4.36 | 5.52 | 6.65 | 8.93 | 7.89 | 7.84 | 6.81 | 6.61 | 6.69 | 7.01 | 5.87 | 4.66 | 4.40 | ||||||
| Thermo Fisher Scientific Inc. | 4.58 | 3.86 | 4.34 | 4.87 | 4.05 | 3.73 | 4.73 | 5.04 | 5.55 | 5.14 | 4.99 | 4.05 | 4.87 | 4.81 | 4.73 | 4.40 | 5.40 | 5.20 | ||||||
| Vertex Pharmaceuticals Inc. | — | 8.82 | 10.40 | 9.13 | 8.42 | 10.41 | 10.78 | 12.12 | 12.35 | 10.39 | 11.16 | 10.10 | 9.73 | 9.68 | 8.56 | 9.26 | 8.85 | 8.17 | ||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
Sales per share
= (Sales to customersQ2 2026
+ Sales to customersQ1 2026
+ Sales to customersQ4 2025
+ Sales to customersQ3 2025)
÷ No. shares of common stock outstanding
= (25,310,000,000 + 24,062,000,000 + 24,564,000,000 + 23,993,000,000)
÷ 2,409,898,597 = 40.64
3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.
4 Q2 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= 259.27 ÷ 40.64 = 6.38
5 Click competitor name to see calculations.
The analysis of the Price-to-Sales (P/S) ratio from April 2022 to June 2026 reveals a distinct valuation cycle characterized by initial compression followed by a significant expansion. The ratio transitioned from a period of moderate decline and stability into a phase of rapid growth, driven primarily by share price appreciation.
- Share Price Dynamics
- A period of volatility and decline is observed between April 2022 and October 2023, with the share price falling from 180.46 US$ to a low of 145.60 US$. Following this trough, a consistent upward trajectory emerged, culminating in a peak of 259.27 US$ by June 2026. This movement indicates a substantial increase in market valuation over the final two years of the period.
- Sales per Share Trends
- Sales per share remained relatively stable, exhibiting less volatility than the share price. After a slight dip to 34.59 US$ in July 2023, a steady growth pattern is evident, with the value rising to 40.64 US$ by June 2026. This reflects a consistent, albeit modest, increase in the revenue generated per share.
- P/S Ratio Interpretation
- The P/S ratio experienced a downward trend in the first half of the analyzed period, reaching a minimum of 4.01 in October 2023. A phase of consolidation followed through 2024, with the ratio fluctuating between 4.25 and 4.55. A sharp expansion occurred starting in 2025, where the ratio climbed from 4.51 in March to 6.38 by June 2026. This acceleration demonstrates that the market assigned a higher premium to each dollar of sales toward the end of the period, as the share price growth significantly outpaced the growth in sales per share.
AI Ask an analyst for more
Price to Book Value (P/BV)
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,409,898,597 | 2,407,216,971 | 2,409,898,936 | 2,409,295,102 | 2,408,338,872 | 2,406,073,279 | 2,407,616,693 | 2,407,622,972 | 2,407,243,667 | 2,406,679,183 | 2,408,767,228 | 2,407,278,620 | 2,598,969,594 | 2,598,734,075 | 2,604,286,303 | 2,614,483,607 | 2,629,179,895 | 2,631,401,804 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||
| Total Johnson & Johnson shareholders’ equity (in millions) | 84,971) | 81,186) | 81,544) | 79,277) | 78,473) | 78,109) | 71,490) | 70,158) | 71,538) | 70,020) | 68,774) | 71,228) | 75,149) | 70,869) | 76,804) | 74,599) | 76,357) | 74,709) | ||||||
| Book value per share (BVPS)2 | 35.26 | 33.73 | 33.84 | 32.90 | 32.58 | 32.46 | 29.69 | 29.14 | 29.72 | 29.09 | 28.55 | 29.59 | 28.91 | 27.27 | 29.49 | 28.53 | 29.04 | 28.39 | ||||||
| Share price1, 3 | 259.27 | 226.10 | 240.86 | 192.94 | 169.56 | 155.38 | 157.25 | 165.86 | 159.64 | 151.18 | 156.55 | 145.60 | 167.53 | 163.70 | 158.24 | 172.31 | 174.52 | 180.46 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||
| P/BV ratio4 | 7.35 | 6.70 | 7.12 | 5.86 | 5.20 | 4.79 | 5.30 | 5.69 | 5.37 | 5.20 | 5.48 | 4.92 | 5.79 | 6.00 | 5.37 | 6.04 | 6.01 | 6.36 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | 229.63 | 102.40 | 58.73 | 48.87 | 36.12 | 29.97 | 20.61 | 20.62 | 19.68 | 15.52 | 16.06 | 16.76 | 16.59 | ||||||
| Amgen Inc. | — | 19.37 | 22.99 | 17.91 | 20.63 | 24.36 | 26.61 | 22.86 | 28.34 | 33.25 | 24.94 | 17.87 | 19.19 | 23.95 | 35.01 | 39.30 | 54.46 | 138.87 | ||||||
| Bristol-Myers Squibb Co. | 5.94 | 6.17 | 6.61 | 5.01 | 5.06 | 5.70 | 6.98 | 6.60 | 6.01 | 5.49 | 3.35 | 3.72 | 3.97 | 4.46 | 4.88 | 4.85 | 4.90 | 5.07 | ||||||
| Danaher Corp. | 2.39 | 2.60 | 2.82 | 3.05 | 2.60 | 2.70 | 3.00 | 3.68 | 3.82 | 3.51 | 3.47 | 2.78 | 3.65 | 3.33 | 3.64 | 3.77 | 4.36 | 4.36 | ||||||
| Eli Lilly & Co. | — | 28.21 | 36.91 | 33.55 | 33.19 | 47.74 | 57.93 | 56.45 | 59.24 | 57.94 | 65.80 | 49.10 | 44.75 | 33.11 | 29.36 | 33.27 | 34.00 | 29.75 | ||||||
| Gilead Sciences Inc. | — | 7.08 | 8.07 | 6.85 | 6.96 | 6.42 | 7.36 | 6.36 | 5.15 | 4.61 | 4.01 | 4.50 | 4.63 | 4.72 | 4.90 | 4.63 | 3.82 | 3.91 | ||||||
| Merck & Co. Inc. | — | 6.09 | 5.82 | 4.04 | 4.12 | 4.32 | 4.99 | 5.73 | 6.53 | 8.00 | 8.68 | 6.35 | 6.96 | 6.38 | 6.07 | 5.63 | 5.12 | 5.44 | ||||||
| Pfizer Inc. | — | 1.67 | 1.78 | 1.49 | 1.59 | 1.50 | 1.68 | 1.70 | 1.92 | 1.74 | 1.75 | 1.80 | 2.04 | 2.14 | 2.48 | 2.83 | 3.21 | 3.37 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.40 | 2.29 | 2.62 | 2.22 | 1.98 | 2.09 | 2.67 | 3.14 | 4.27 | 3.83 | 3.96 | 3.58 | 3.49 | 3.52 | 3.77 | 3.75 | 3.21 | 3.65 | ||||||
| Thermo Fisher Scientific Inc. | 4.03 | 3.36 | 3.62 | 4.18 | 3.46 | 3.24 | 4.09 | 4.36 | 4.96 | 4.80 | 4.57 | 3.88 | 4.84 | 4.99 | 4.83 | 4.46 | 5.47 | 5.23 | ||||||
| Vertex Pharmaceuticals Inc. | — | 5.56 | 6.69 | 6.18 | 5.60 | 7.01 | 7.24 | 8.24 | 8.64 | 5.71 | 6.26 | 5.90 | 5.98 | 6.18 | 5.50 | 6.18 | 6.19 | 5.95 | ||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
BVPS = Total Johnson & Johnson shareholders’ equity ÷ No. shares of common stock outstanding
= 84,971,000,000 ÷ 2,409,898,597 = 35.26
3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.
4 Q2 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= 259.27 ÷ 35.26 = 7.35
5 Click competitor name to see calculations.
The Price to Book Value (P/BV) ratio exhibits significant volatility over the analyzed period, reflecting a fluctuating relationship between market valuation and the company's accounting equity. While the ratio initially fluctuated between 5.37 and 6.36 in 2022, it experienced a notable compression phase before expanding to a period high by mid-2026.
- Share Price Dynamics
- Market valuation underwent a period of contraction and subsequent expansion. The share price declined from a peak of 180.46 in April 2022 to a low of 145.60 in October 2023. Following this trough, a strong recovery trend emerged, characterized by a steady climb that culminated in a peak of 259.27 by June 2026, driving the overall increase in the P/BV ratio.
- Book Value per Share (BVPS) Trends
- The book value per share remained relatively stable for the first half of the observed period, oscillating between 27.27 and 29.59. A definitive upward shift occurred starting in March 2025, where BVPS rose to 32.46 and continued a gradual ascent to 35.26 by June 2026. This indicates a steady growth in the underlying net asset value per share.
- P/BV Ratio Analysis
- The P/BV ratio reached its lowest point of 4.79 in March 2025, signaling a period where the market price was closest to the book value. However, the subsequent acceleration in share price outpaced the growth in book value, leading to a rapid valuation expansion. The ratio climbed from 4.79 to a maximum of 7.35 by June 2026, indicating a higher market premium attributed to the company's assets toward the end of the period.
- Correlation and Valuation Insights
- The data indicates that the P/BV movements were primarily driven by share price volatility rather than changes in book value. For much of 2022 through 2024, the stability of the BVPS meant that the P/BV ratio served as a direct proxy for market sentiment. The sharp increase in the ratio during 2025 and 2026 suggests an increase in investor confidence or an expectation of higher future returns relative to the company's tangible asset base.
AI Ask an analyst for more